Fabio Lopez
Director/Miembro de la Junta en Sellas Life Sciences Group Ltd. .
Perfil
Fabio Lopez is currently a Director at Sellas Life Sciences Group Ltd.
He was previously a Director at SELLAS Life Sciences Group, Inc. from 2017 to 2018.
Cargos activos de Fabio Lopez
Empresas | Cargo | Inicio |
---|---|---|
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Director/Miembro de la Junta | 29/12/2017 |
Antiguos cargos conocidos de Fabio Lopez.
Empresas | Cargo | Fin |
---|---|---|
SELLAS LIFE SCIENCES GROUP, INC. | Director/Miembro de la Junta | 27/07/2018 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
SELLAS LIFE SCIENCES GROUP, INC. | Health Technology |
Empresas privadas | 1 |
---|---|
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Health Technology |
- Bolsa de valores
- Insiders
- Fabio Lopez